SHAPING FUTURE PERFORMANCE ANNUAL REPORT 2025 SHAPING FUTURE PERFORMANCE Despite a challenging trading environment in FY 2025, we made further progress in delivering high performance polymer solutions that help shape future performance for our…
SHAPING
FUTURE
PERFORMANCE
ANNUAL REPORT 2025
SHAPING FUTURE
PERFORMANCE
Despite a challenging trading environment in FY 2025,
we made further progress in delivering high performance
polymer solutions that help shape future performance
for our customers.
From aerospace, automotive, electronics and energy to
medical, our products are embedded in the ‘mission‑critical’
applications of today such as smartphones, ABS braking
systems and medical devices, as well as supporting the
innovations of tomorrow.
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
1
69
72
74
82
86
93
129 Consolidated income statement
130 Consolidated statement
of comprehensive income
131 Balance sheets
132 Cash flow statements
133 Consolidated statement
of changes in equity
134 Company statement
of changes in equity
135 Notes to the financial statements
S trong volumes offset by sales mix,
FX and China start-up; profit
improvement plan underway
2
Victrex at a glance
4
Chair’s statement
6
Our markets and megatrends
8
Our business model
10 Our strategy
12 Overview of strategy
14 Key performance indicators
16 Stakeholder engagement
19 Delivering for our stakeholders
20 Financial review
26 Divisional & end market summary
28 Risk
35 Going concern and viability statement
38 Sustainability report
Cover:
Image of Hybrid Flexible Pipe/Magma
Pipe – based on VICTREX TM PEEK
materials – is courtesy of and
copyrighted to TechnipFMC.
Introduction from the Chair
Board of Directors
Statement of corporate governance
Nominations Committee report
Audit Committee report
Corporate Responsibility
Committee report
95 Directors’ remuneration report
117 Directors’ report – other
statutory information
121 Statement of Directors’ responsibilities
in respect of the Annual Report and the
financial statements
122 Independent auditors’ report to
the members of Victrex plc
SHAREHOLDER INFORMATION
178 Five-year financial summary and
Cautionary note regarding
forward‑looking statements
179 Financial calendar
180 Advisors
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
STRONG VOLUMES OFFSET BY SALES MIX, FX AND CHINA START-UP;
PROFIT IMPROVEMENT PLAN UNDERWAY
Group sales volume tonnes
4,164 +12%
4,164
25
Group revenue £m
292.7 +1%
292.7
25
291.0
24
3,731
24
23
3,598
23
33.8 +44%
33.8
25
24
307.0
Basic earnings per share p
24
72.5
59.1
80.0
23
59.56p flat
32.0
19.8
70.9
23
46.4
Dividend per share p (regular)
32.0 +62%
25
23.4
23
46.4 -21%
25
24
Reported profit before tax £m
Underlying profit before tax1 £m
25
59.56
24
59.56
23
59.56
KEY POINTS:
STRONG VOLUMES, UP 12%
•
FY 2025 Group volumes 4,164 tonnes (FY 2024: 3,731t) driven
by VARs* and Energy & Industrial
REVENUE UP 1%
•
Average selling price (‘ASP’) £70/kg (FY 2024: £78/kg); c80% of
year-on-year movement due to sales mix and FX; like-for-like
pricing broadly stable in non-VAR/Energy & Industrial end
markets
•
Medical revenue down 5% at £58.8m driven by Spine; 7%
growth in Non-Spine business (including 12% growth in
Non-Implantable Medical)
UNDERLYING PBT DOWN 21% TO £46.4M
ON FX, CHINA COSTS & SALES MIX; H2 PBT
IN LINE WITH H1
•
FY 2025 underlying PBT down 10% in constant FX
•
Reported PBT up 44% at £33.8m after £12.6m
(FY 2024: £35.7m) of exceptional items
•
FY 2025 GM in line with guidance at 45.3%; down 90 bps
on mix, £8m impact from new China plant** & FX
•
Improved underlying operating cash conversion1 of 121%
(FY 2024: 114%)
•
FY 2025 net debt £24.8m (FY 2024: £21.1m) (including cash of
£24.2m (FY 2024: £29.3m)) with RCF repaid. Net debt/EBITDA
0.34x at year-end
PROFIT IMPROVEMENT PLAN UNDERWAY
•
Profit Improvement Plan underway targeting at least £10m of
further savings; full year benefits in FY 2027, significantly
building on existing self-help and ‘Go to Market’ improvements
•
Broader review of operations to be implemented in FY 2026,
targeting further commercial, cost and operating efficiencies,
driving business simplification
UPDATED CAPITAL ALLOCATION POLICY:
DIVIDEND MAINTAINED
•
Reflecting all stakeholder interests; new net debt/EBITDA1 range
of 0.5x-1.0x targeted
•
Dividends maintained vs FY 2024 (proposed final FY 2025
dividend payment 46.14p (FY 2024: 46.14p/share))
•
Dividends maintained at current level, provided net debt/
EBITDA1 target range not exceeded; excess cash returns available
via share buybacks or special dividends when net debt/EBITDA1
moves sustainably below 0.5x
- Value Added Resellers.
** China start-up impact reflects a full year annualised operating loss of £8m, with a year on year adverse impact of £4m.
1 Alternative performance measures are defined in note 26.
Annual Report 2025 – Victrex plc
1
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
VICTREX AT A GLANCE
OUR STRATEGIC
ROADMAP
OUR
PURPOSE
We bring transformational
and sustainable solutions
that address world material
challenges every day
STRATEGY
A world leader in value creation through
PEEK & PAEK based polymer solutions
STRATEGIC IMPERATIVES
(MUST WINS)
DRIVE – core business
DIFFERENTIATE – through innovation
CREATE & DELIVER – future value
UNDERPIN – safety, quality, sustainability
OUR VALUES
Passion
Innovation
Performance
PEOPLE & CULTURE
Safety, Sustainability & Accountability
Innovation
Service for customers
Delivering with speed
A SUSTAINABLE BUSINESS
PEOPLE
PLANET
PRODUCTS
Support our local communities and
inspire STEM-based careers. Support
a DE&I agenda for our employees.
Minimise our use of resources and our
environmental impact (carbon, water
& waste) and support Biodiversity.
Deliver sustainable products to our
customers which enable environmental
and societal benefits (e.g. CO2 reduction).
Sustainability report
Pages 38 to 67
2
Victrex plc – Annual Report 2025
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
OUR PURPOSE: BRINGING
TRANSFORMATIONAL
& SUSTAINABLE SOLUTIONS
Victrex’s products are aligned to global megatrends, supporting CO2 reduction and energy efficiency or
providing clinical benefit in a wide range of everyday applications. VICTREX™ PEEK polymers typically replace
metal with a lighter, more durable and more sustainable alternative. As a market leader, through our core
product portfolio, or our more differentiated and ‘semi-finished’ products, we develop new uses for VICTREX™
PEEK, creating new markets, delivering solutions for our customers and driving value for our investors.
OUR SOLUTIONS
AEROSPACE
20,000+
aircraft flying with Victrex solutions
ENERGY & INDUSTRIAL
75m+
100m+
VICTREX™ PEEK seal rings in use today
machines operate using Victrex solutions
AUTOMOTIVE
500m+
VICTREX™ PEEK based applications in use
ELECTRONICS
4bn+
mobile devices using APTIV™ film
MEDICAL
15m+
implanted medical devices using
VICTREX™ PEEK to date
OUR BUSINESS
1,100+
employees globally
40+
countries served
53%
of revenues from sustainable products#
c.5%–6%
of sales invested in R&D##
100%
of our global electricity is from renewable sources###
(where the market exists; see page 57)
30–40%
typical weight saving using VICTREXTM
PEEK vs metal
Note: Source data available on request.
Sustainable products are defined as those which offer quantifiable environmental or societal benefit. These are primarily in Automotive, Aerospace
(supporting CO2 reduction) and Medical (supporting improved patient outcomes). Some applications are also in Energy & Industrial (e.g. wind and
renewable energy applications) and Electronics (supporting energy efficiency, e.g. home appliances). Volumes from Oil & Gas are excluded, as are
Value Added Resellers volumes currently, due to the lack of full clarity on exact end market destinations. Sustainable products represented 53%
of Group revenues in FY 2025 (FY 2024: 56%).
The Group targets 5–6% of Group revenues to be spent on R&D expenditure, being a leading indicator of the Group’s ability to innovate into new
applications, supporting future growth.
For all countries where the market exists via either retail supply contracts or offset by certificated EACs. This applies to all future references to 100%
electricity from renewable sources throughout this report.
Annual Report 2025 – Victrex plc
3
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
CHAIR’S STATEMENT
ADDRESSING OUR
CHALLENGES – DELIVERING
OUR OPPORTUNITIES
DEAR SHAREHOLDER,
OVERVIEW
Victrex and the wider chemical industry
continued to see a number of significant
challenges during FY 2025, including
variable end market demand, competition
and geo-political uncertainty. Despite these
challenges, we saw strong progress in sales
volumes, which grew 12%, including a
record annual increase in our sales pipeline.
THROUGH INCREMENTAL
COST ACTIONS AND A
PROFIT IMPROVEMENT
PLAN, THE BOARD IS FULLY
FOCUSED ON ENHANCING
PROFITABILITY, AS WELL
AS DELIVERING ON OUR
LONG‑TERM GROWTH
OPPORTUNITIES.
THE STRONGER
FOUNDATIONS WE HAVE
BUILT OVER RECENT YEARS
– IN PEOPLE, ASSETS AND
CAPABILITY – WILL HELP TO
UNDERPIN OUR FUTURE.
Dr Vivienne Cox DBE
Chair
Although volumes improved, the Group
saw lower profitability partly due to the
external environment, including currency,
as well as Company specific factors like
start-up costs in our China manufacturing
facility. Further information is shown in the
Financial review on pages 20 to 27.
IMPROVING OUR PERFORMANCE
Through incremental cost actions in
FY 2026 and a Profit Improvement Plan –
to be implemented by our new CEO and
targeting at least £10m of cost savings – the
Board is fully focused on enhancing
profitability and financial performance. This
will include targeted actions to simplify our
business, on cost of manufacture and our
overhead base.
With our major investment phase now
behind us, the stronger foundations we have
built over recent years – in people, assets
and capability – will help to underpin our
future. These include increased digitalisation
and an enhanced Sales team structure,
providing a stronger customer facing platform
to deliver growth. The Board, our Management
Team and our employees are all aligned to
unleashing and unlocking the inherent value
in our business.
OUR PURPOSE: BRINGING
TRANSFORMATIONAL AND
SUSTAINABLE SOLUTIONS
Victrex has a clear purpose to bring
transformational and sustainable solutions
to the performance challenges faced by
our customers. We serve several key end
markets, with our value proposition to
customers being closely aligned to global
megatrends such as CO2 reduction, energy
efficiency or enhancing clinical benefit.
Our products bring environmental, technical
or medical benefits. In the Aerospace and
Automotive industries for example, this is
through lighter, more durable and faster to
process materials supporting CO2 reduction,
or in Medical, supporting better patient
4
Victrex plc – Annual Report 2025
outcomes. Victrex materials support
‘mission-critical’ applications today as well
as being part of the innovation programmes
of tomorrow. Further information is in the
CEO’s review of strategy on pages 12 and 13.
SAFETY: EMBEDDED IN
OUR CULTURE
Victrex has a Zero Accidents, Zero Incidents
goal across our global organisation. Our
recordable injury frequency rate has reduced
by 77% since FY 2021, thanks to a significant
focus on process safety. During the year,
we maintained a strong safety record, with
our recordable injury frequency rate (‘RIFR’)
slightly improving to 0.16 (FY 2024: 0.18),
better than the OSHA industry average (1.5).
Victrex also secured the Chemical Industries
Association (‘CIA’) Process Safety
Leadership award.
STRATEGY & INVESTMENT CASE:
FOCUS ON IMPROVED EXECUTION
Victrex’s strategy focuses on value creation
through PEEK and PAEK materials across our
two business areas of Sustainable Solutions
and Medical. Our innovative culture and
application development know-how seek
to deliver performance benefits for our
customers and create value for shareholders.
Victrex delivers solutions, not just products.
Our addressable market opportunity is at
least 5x current levels and we remain confident
in our long-term investment case.
In a challenging period – and reflecting
the appointment of James Routh as our
new CEO from 1 January 2026 – we are fully
focused on improving our strategy execution
to unlock our true potential.
INCREASING OUR
DIFFERENTIATION
Whilst competition in PEEK has been
evident for over 20 years, FY 2025 saw
more competitive pressure within specific end
markets. Victrex continues to differentiate
to maintain a leadership position – in our
strategy, our Go to Market approach and
our product offering. Our portfolio includes
our core polymer business and more
semi-finished and differentiated products
like APTIV™ film and our mega-programmes.
Differentiation also comes through technical
service, IP and our unique manufacturing
process, with backward integration into key
raw materials. Our competitive positioning
has been built up over many years and
STRATEGIC REPORT
CORPORATE GOVERNANCE
includes know-how and patents. We invest
5–6% of sales every year to support R&D.
STRONG SUSTAINABILITY
CREDENTIALS
Our Sustainability framework focuses
on three pillars: People, Planet & Products.
The environmental and societal benefits of
VICTREX™ PEEK products will continue to
increase in importance, as the need for CO2
reduction, energy efficiency or improved
patient outcomes becomes more critical.
During the year, we were able to demonstrate
that the climate impact of VICTREX™ PEEK
remains favourable versus the industry average,
based on validated Lifecycle Analysis (‘LCA’).
Our People agenda includes employee
volunteering for Biodiversity projects where
we operate, Science, Technology, Engineering
& Maths (‘STEM’) activities, which we have
demonstrated can help our future talent
pipeline, and a strong apprenticeship
programme. Further detail is shown in the
Sustainability report on pages 38 to 67.
CAPITAL ALLOCATION &
DIVIDENDS
We focus on growth investment first and
foremost, with investment in R&D, incremental
M&A or to support our strategy.
With the conclusion of our major investment
phase last year, including upgrades to our
UK assets and our new China facility, we see
good medium to long-term prospects for
shareholder returns, as profits and cash flow
improve. Alongside our Profit Improvement
Plan, we remain focused on retaining
balance sheet strength.
As a result, the Board has, taking account of
all stakeholder interests, set a new target for
net debt / EBITDA of 0.5x – 1.0x, with
dividends maintained at FY 2024 levels.
Additional term debt will be secured prior to
payment of our FY 2025 final dividend
(proposed at 46.14p/share) in February
2026. Dividends will be maintained at these
levels provided the net debt / EBITDA range
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
is not exceeded. It makes our updated
capital allocation policy more sustainable for
our business, particularly when partnering
with major customers, who value balance
sheet strength. The option of returning
excess cash via share buybacks or special
dividends remains, once net debt / EBITDA
moves sustainably below 0.5x.
to 76%. Victrex was also included in
The Sunday Times Best Places to Work
and was named as the Company of the Year
by the Chemical Industries Association (‘CIA’).
A summary of our employee engagement
activities, including the work of our
Workforce Engagement Non-executive
Director, is shown on page 81.
Further information is shown in the Financial
review on pages 20 to 27.
In our Equal Opportunities, Diversity, Equity
& Inclusion (‘DE&I’) journey, the Group
made good progress this year. We now have
40% of our senior leadership group
comprising females, as part of our females
in leadership target of 40% by 2030 (based
on FTSE Women Leaders methodology). Our
employee resource groups (‘ERGs’) reflect
the international nature of our operations.
OUR BOARD: NEW CEO
During the year, Jakob Sigurdsson signalled
his intention to retire as CEO. We thank
Jakob for his passion and contribution to
the Group over the last eight years. Our
foundations are stronger and our focus is
very clearly on improving execution.
I am delighted to welcome James Routh
who joins us as CEO on 1 January 2026, after
a rigorous recruitment process. James joins us
from AB Dynamics plc, where he delivered
significant revenue and profit growth. His
experience in automotive and aerospace
companies is also aligned to Victrex and our
significant growth opportunities. James will
lead our Profit Improvement Plan in FY 2026.
Jane Toogood, who chaired our Corporate
Responsibility (‘CR’) Committee, also
stepped down as a Non-executive Director in
February 2025, after nine years on the Board.
We thank Jane for her many contributions to
Board debate and governance. We continue
to place a strong emphasis on governance,
as well as ensuring the Board has the skills
and experience to support delivery of our
strategy. Biographies can be found on
pages 72 and 73.
PEOPLE, CULTURE, DIVERSITY,
EQUITY & INCLUSION
We continue to support our employees
through training, flexible working and
supportive policies. In FY 2026 we will
conduct another full Employee Engagement
Survey, with our 2025 UK Engagement
Survey showing a further improvement
This very challenging period for the Group
has underlined the resilience of our global
employee base. With the absence of an
annual bonus or long-term incentives since
FY 2022, this year’s partial reward reflected
the achievement of strategic and non-profit
metrics (including strong cash conversion)
and the importance of employee retention,
reflected in our share-based long-term
incentives. The Remuneration Committee
used its discretion to reduce bonus payments
by one third for the Executive Directors and
VMT members. Further detail is shown in
the Remuneration Committee report on
pages 95 to 116. On behalf of the Board,
I would like to thank every one of Victrex’s
employees for their continued contribution
and adaptability to drive change and
improve our performance.
OUTLOOK
Whilst we remain mindful of macro-economic
and industry challenges, we are targeting
solid progress vs FY 2025, with an H2
weighting to reflect seasonality and the
higher FX headwind in H1 2026.
Although FY 2026 will be a transitional year,
our foundations are strong, with a
differentiated product portfolio across key
end markets and an addressable market
five times current levels, offering significant
long-term growth in demand for PEEK.
We will create a simpler and focused growth
business, improving cost to serve and driving
significant value creation for all stakeholders.
Dr Vivienne Cox DBE
Chair
2 December 2025
SECURING OUR
FUTURE THROUGH
TALENT: Victrex has a
strong apprenticeship
programme which
supports our talent
agenda, with 48
current apprentices.
Annual Report 2025 – Victrex plc
5
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
OUR MARKETS AND MEGATRENDS
DIVERSE GROWTH
OPPORTUNITIES
Medical
20% of
revenues
VAR
We have long-term megatrends in our favour. Our sustainable products support
CO2 reduction, energy efficiency or clinical outcomes, with a diverse mix of growth
opportunities across our end markets. We differentiate by providing solutions for
customers, not just products, creating new markets through our innovation know-how.
END MARKETS
Sustainable
Solutions
80% of
revenues
MARKET OPPORTUNITY
AEROSPACE
(TRANSPORT MARKETS
24% OF SALES VOLUME)
49,000
new passenger and
freight aircraft by 2044
SUSTAINABLE SOLUTIONS
Source: Airbus
AUTOMOTIVE
(TRANSPORT MARKETS
24% OF SALES VOLUME)
ELECTRONICS
(11% OF SALES VOLUME)
200g
potential PEEK/car on EV platforms
(increase from current 11g average over the
long term, based on 800V electric vehicle)
38bn+
connected devices
by 2030
Source: GSMA Intelligence
ENERGY & INDUSTRIAL
(17% OF SALES VOLUME)
27%
forecast increase in
energy use by 2040
Source: IEA
VAR VALUE ADDED RESELLERS
MEDICAL
(43% OF SALES VOLUME)
6
MEDICAL
(5% OF SALES VOLUME
& 20% OF REVENUES)
Victrex plc – Annual Report 2025
VARs form a key part of our route to market. VARs
compound or process VICTREX™ PEEK into stock shapes
for onward processing, serving multiple end markets.
6.5% CAGR
forecast for global medical device
industry revenue growth 2025–32
Source: Alphasense
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
5x
Victrex’s assessment of the addressable market for
PEEK polymer applications vs current levels
Visit www.victrexplc.com to see how we are shaping
future performance across our end markets
MEGATRENDS
OPPORTUNITY FOR VICTREX™ PEEK
FLY LIGHTER & REDUCE FUEL COST
10X PEEK CONTENT INCREASE PER PLANE
•
Lighter weight and CO2 reduction with more efficient
manufacturing using PEEK, PAEK and composites mean fuel
saving – a strategic imperative for the Aerospace industry.
•
Opportunities to support reduction of plane delivery backlogs
through more efficient manufacturing.
•
Commercialisation of lighter structural composite parts
(wing and fuselage structures).
•
Part of Airbus Clean Sky 2 programme & Advanced Air Mobility
(‘AAM’) programmes.
•
Opportunity to move from c0.5 tonne to over 5 tonnes of PEEK
per plane over the longer term (c.10x content increase).
CO2 REDUCTION, DURABILITY AND ELECTRIFICATION
INCREASE PEEK CONTENT PER VEHICLE
•
Fuel efficiency, CO2 reduction, safety and reliability
improvements resulting from consumer and regulatory trends.
•
Potential of >200g PEEK per car (long‑term opportunity),
based on EVs vs industry average of 11g of PEEK/car today.
•
Transition from internal combustion engines (‘ICE’) to electric
vehicles (‘EVs’) as electrification is mandated in many regions.
•
Multiple opportunities in EVs with business wins.
•
Majority of existing ICE applications translate across EVs.
THINNER & SMARTER DEVICES
ENERGY EFFICIENCY AND THERMAL MANAGEMENT
•
Increased functionality of smartphones and devices.
•
•
Industry trends for mobile devices that are thinner and smarter
(whilst performance requirements continue to increase).
Broadening range of applications: semiconductors, mobile
devices and home appliances.
•
AI opportunities.
•
Increase in Artificial Intelligence (‘AI’) and new technologies
such as 5G or 6G.
•
Strong capability of PEEK in durability and thermal management.
•
Metal replacement supporting energy efficiency.
ENERGY TRANSITION
PERFORMANCE IN TRADITIONAL & NEW ENERGY
•
Higher performance requirements from exploration into
extreme environments, as well as the energy transition.
•
Continuing opportunities in oil & gas exploration and processing
equipment, alongside renewable or ‘new’ energy.
•
More efficient manufacturing processes create more data
and connectivity requirements in Industrial end markets.
•
Alternative solutions for metal replacement in traditional energy;
Magma Composite Pipe/Hybrid Flexible Pipe.
•
Drive new application areas in Industrial, including food, robotics
and opportunity for PEEK in response to PFAS regulations.
Victrex engages in strategic or development relationships with end customers. VARs then supply ‘specified’ VICTREX™ PEEK
grades to tier 1 or end customers in several industrial end markets (e.g. Automotive, Energy & Industrial), thereby forming
a key part of global supply chains. Speed, security of supply and product quality are key requirements.
AGEING GLOBAL POPULATION
•
People are living longer: focus on maintaining quality of life
and activity levels, driving better patient outcomes.
•
Greater demand for alternative and non-metal solutions
in Non-Spine.
•
Growing concern about the effects of metal-based implantable
materials, e.g. cobalt chrome and PFAS materials.
SUPPORT IMPROVED PATIENT OUTCOMES
•
Significant growth in Non-Spine, e.g CMF, Active Implantable
devices, Cardio applications. Differentiation through Trauma
and Knee applications.
•
Leveraging clinical data to drive PEEK adoption.
•
3D printed Porous PEEK approved to support
greater bone in-growth in spinal applications.
Annual Report 2025 – Victrex plc
7
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
OUR BUSINESS MODEL
SUSTAINABLE BY
NATURE AND DESIGN
WHO WE ARE
Victrex was formed in 1993 following
a management buy-out from ICI, with
VICTREX™ PEEK polymers having
their roots in the 1970s when the
product was developed.
Today, we are a world leader in PEEK,
serving customers in 40 countries and
with a strong culture of innovation.
Every day, millions of people rely
on applications which contain our
sustainable products and materials,
from smartphones, aeroplanes and
cars to energy production and
medical devices.
SHAPING FUTURE
PERFORMANCE
Our strategy, as a world leader in
value creation through PEEK & PAEK
polymer materials, is to develop
and manufacture products which
enable environmental & societal
benefits for our customers and
society. Our products offer
lightweighting, durability, faster
processing and clinical outcomes,
which help to shape future
performance for our customers.
WHAT WE DO
- A DIFFERENTIATED & SUSTAINABLE BUSINESS MODEL
Our products offer a unique combination of properties, supporting CO2 reduction
in Aerospace & Automotive through lightweighting and faster processing, and
improving patient outcomes in medical devices. Beyond manufacturing VICTREX™
PEEK polymers, we also differentiate through semi-finished and differentiated
products such as APTIV™ film, composite tape and pipe, helping to deliver
solutions for customers. With our People, Planet & Product-based ESG pillars,
we seek to minimise our use of resources (energy, carbon and water).
- WE ALIGN TO GLOBAL MEGATRENDS; WE DELIVER SOLUTIONS
We identify megatrends, such as CO2 reduction or energy efficiency, where our
polymers can offer a performance advantage vs metal or incumbent materials.
We ‘hunt’ new use cases for VICTREX™ PEEK, understanding customer needs
and delivering solutions for them, in turn creating new markets for our products.
- WE HAVE A STRONG CULTURE OF INNOVATION
Our culture is built on innovation, with a focus on PEEK/PAEK and the high
performance materials area, beyond simply manufacturing polymers. We have
a high level of technical and digital capability, with investment in Research &
Development representing c.5–6% of annual revenues, and increasing digital
solutions to support our business and our customers. We work with partners to
bring new and enhanced products to our customers, shaping future performance.
UN SUSTAINABLE DEVELOPMENT GOALS (‘SDGs’)
Key to strategy
Drive core business
Differentiate through innovation
Create and deliver future value
nderpin through safety,
U
sustainability and capability
8
Victrex plc – Annual Report 2025
We are aligned to the UN’s Sustainable Development Goals 2030, including
validation of decarbonisation goals for the Science Based Targets initiative (‘SBTi’).
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
HOW WE CREATE VALUE
4. WE HAVE MANUFACTURING & PRODUCT DIFFERENTIATION
Our strategy and unique manufacturing process (Type 1 PEEK) differentiate us from
competitors, with >200 patents in place or pending, and know-how helping us to
manufacture the widest range of PEEK products, including Type 2 PEEK (UK & new
China facilities). Safety is our highest priority, with efficient and well-invested assets.
FOR CUSTOMERS
By partnering with customers in the
development of new applications, we
bring superior products that deliver
long-term performance benefits vs
incumbent materials.
Read more on pages 16 and 17
FOR EMPLOYEES
- WE DRIVE COST EFFICIENCY & CASH GENERATION
Investing in skills, apprenticeships and
training brings significant opportunity
for development. Performance-based
reward drives a high retention rate.
Read more on pages 16 and 17
Our robust financial profile enables us to invest (capex or M&A) in support
of our strategy. Cost efficiency and productivity are key, as we focus on cost
of manufacture, supporting cost to serve. With high value and differentiated
products, we seek to retain a robust balance sheet. After a period of high
investment, cash generation is expected to show continued improvement.
FOR INVESTORS
Continued innovation and opening up
new revenue streams support returns
and cash generation.
Read more on pages 16 and 17
- WE DELIVER SALES AND TECHNICAL DIFFERENTIATION
FOR COMMUNITIES
Our Sales & Technical Service teams help us differentiate with customers through
validation and certification in critical applications. We have strong Regulatory
& Quality teams, partnering with customers in development of new applications
and solutions, helping to drive VICTREX™ PEEK adoption. Our Go to Market
approach includes increasing digital solutions for customers (for example in digital
modelling for an application).
SUPPORTED BY
OUR PEOPLE & CAPABILITY
Over 1,100 talented employees wake up every day focusing on selling more
VICTREX™ PEEK and partnering with customers to shape future performance.
OUR SUPPLIERS & PARTNERS
Engagement with our local
communities enables us to partner
on a range of social responsibility
and environmental programmes.
Read more on pages 16 and 17
FOR SOCIETY & THE PLANET
Our purpose is to bring
transformational & sustainable
solutions, with products which
can enable environmental
or societal benefits.
Read more on pages 16 and 17
We are the only PEEK manufacturer with upstream integration into key
raw materials, supporting long-term security of supply for customers.
Annual Report 2025 – Victrex plc
9
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
OUR STRATEGY
A WORLD LEADER IN VALUE
CREATION THROUGH PEEK
& PAEK POLYMERS
PEEK POLYMER INVENTED
BY ICI IN 1978
SECURITY OF SUPPLY
•
VICTREX: THE FIRST
TO COMMERCIALISE
PEEK POLYMERS
•
Millions of people rely on
our differentiated products
& applications based on
VICTREX™ PEEK every day
DRIVE CORE
BUSINESS:
FOCUS ON PEEK
•
We pioneer new and differentiated
VICTREX™ PEEK based products
and solutions
•
Polymer grades for engineering
needs: granules, powders and
micro pellets...
•
...into PEEK films, PEEK fibres and
thermoplastic composite tapes
DIFFERENTIATE: APPLICATION,
DEVELOPMENT, EXPERTISE
•
We deliver solutions and help customers overcome complex design
and engineering challenges. We accelerate the development of
innovative and sustainable applications across key end markets
INVESTMENT IN INNOVATION
•
c.5–6% of annual
sales invested in R&D
•
Polymer capacity
•
Composite solutions
CREATE: TRANSFORMATIONAL SOLUTIONS
UNDERPIN
10
•
Safety: Safer, Better, Together
•
Quality: in everything we do
•
Sustainability: People, Planet & Products
•
Talent agenda
•
Robust financial position
Victrex plc – Annual Report 2025
Victrex has an integrated supply
chain and the highest PEEK
capacity to global quality standards
•
•
Medical components
•
Polymer Innovation
Centre
•
Digital application &
chemistry solutions
Innovation partnerships and
mega-programmes addressing
global megatrends
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
Annual Report 2025 – Victrex plc
11
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
OVERVIEW OF STRATEGY
STRONGER FOUNDATIONS
IN PLACE; FOCUSED ON
PROFIT IMPROVEMENT
DEAR SHAREHOLDER,
STRONGER FOUNDATIONS
TO SUPPORT DELIVERY
With the conclusion of our major strategic
investment phase last year, those investments
– in people, assets, capability and technology
– will be expected to show a return and help
us unleash our full potential.
Whilst results were in line with our latest
guidance, our FY 2025 financial performance
was weaker compared to the prior year (details
on page 20). Throughout this very challenging
period for Victrex and the global chemical
industry, we have kept the long-term
horizon in sight, whilst addressing our
short-term challenges.
OUR LONG-TERM VALUE
PROPOSITION – WITH
MARKET LEADING
PRODUCTS WHICH
ENABLE ENVIRONMENTAL,
TECHNICAL OR SOCIETAL
PERFORMANCE BENEFITS
– REMAINS STRONG DESPITE
THE TOUGH EXTERNAL
ENVIRONMENT.
OUR FOCUS IS ON
INCREMENTAL PROFIT
IMPROVEMENT ACTIONS
TO ADDRESS CURRENT
CHALLENGES, INCLUDING
STRATEGY EXECUTION,
PORTFOLIO SIMPLIFICATION
AND COST REDUCTION.
Jakob Sigurdsson
CEO
12
Victrex plc – Annual Report 2025
Through enhancing our Go to Market
approach, our sales and R&D organisation
and increasing digitalisation to serve our
customers, we now have stronger
foundations to support delivery.
PROFIT IMPROVEMENT PLAN
Whilst cost control featured high on our
agenda during this challenging period,
we will need to go further in FY 2026.
In what will be a transitional year, with
a CEO succession, our focus will be on
incremental improvement actions to support
delivery and ultimately improve profitability.
We are targeting at least £10m of annual
cost savings, to be delivered by the end of
FY 2027, with initial benefits to be realised
in FY 2026.
A simpler portfolio, improving cost of
manufacture and targeted efficiency
opportunities in our overheads are areas in
focus. Navigating the current external
environment, whilst not sacrificing long-term
opportunities, is the only way to ensure the
value proposition for the use of VICTREX™
PEEK remains strong.
INVESTMENT CASE & VALUE
PROPOSITION
•
We are a world leader and the first
mover in PEEK & PAEK polymers
with strong innovation credentials and
differentiated products; we have the
broadest PEEK portfolio and extensive
performance data on PEEK.
•
Addressable market 5x current
levels: we hunt for new use cases for
VICTREX™ PEEK, with a track record
of delivering performance benefits in
‘mission-critical’ applications, as well as
being part of tomorrow’s innovations.
•
We have a culture of innovation,
helping us to create new markets and
use cases for VICTREX™ PEEK, with R&D
investment at 5-6% of revenues (pa),
supporting our strong growth pipeline.
•
We are aligned to global megatrends
like CO2 reduction. Sustainable products
form 53% of Group revenues.
•
We have a unique and differentiated
manufacturing process – which
supports our competitive differentiation.
•
Our financial profile will continue
to improve as investments are now in
place. We maintain attractive returns
(14% average return on invested capital
(ROIC) over five years) and strong
cash conversion.
DIFFERENTIATING OUR BUSINESS
With more competition in some of our less
differentiated end markets this year, we are
increasing the differentiation and innovation
that Victrex has been known for:
•
Enhancing customer experience: our
sales and R&D teams are operating with
greater regional focus to unlock new
opportunities and serve customers.
•
Increasing digitalisation: greater use
of digital tools for Sales and R&D teams
(e.g. digital modelling) and leveraging
our ERP system to deliver solutions for
customers (not just products).
•
Improving the speed of our
innovation and technical service:
a key credential of Victrex has always
been how we support customers with
technical service.
STRATEGIC REPORT
CORPORATE GOVERNANCE
STRATEGIC PROGRESS
Q1: MEDICAL
US FDA approval for first 3D
printed Porous PEEK spinal cage
based on PEEK-OPTIMA™
Read more on pages 20–27
Q2: SAFETY
20 years without a Lost Time
Accident (‘LTA’) at our Seal
Sands UK manufacturing facility
Read more on page 63
Q3: MEGA-PROGRAMMES
Petrobras awards technological
order contract to TechnipFMC
for Hybrid Flexible Pipe (Magma)
based on VICTREX™ PEEK
Read more on pages 20–27
Q4: CHINA
Commercial sales from our new
manufacturing facility in China,
with initial production of Victrex
‘Elementary’ PEEK
Read more on pages 20–27
STRATEGY AND STRATEGIC
PRIORITIES
We are restless to improve our
financial performance.
Whilst our strategy as a world leader
in value creation through PEEK and PAEK
polymers remains appropriate, we will
blend our position as a product leader
with improved operational excellence
and customer intimacy.
Addressing our short-term challenges
to drive our long-term opportunities also
means leveraging our differentiated
strategy – with a core polymer business,
semi-finished products like film, composite
tape or pipes, and a selected number of
potentially game-changing mega-programmes.
Our strategic priorities are shown on
pages 16 and 17 with each and every one of
our employees aligned to our ‘Must Win’
agenda, whether that be in our customer
facing, operations or support functions.
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
FY 2025 IN REVIEW & THE ROAD
TO IMPROVED DELIVERY
Despite a weaker profit performance, the
early benefits of our Go to Market approach
and Project Vista programme started to be
realised. Sales volume increased by 12% and
our sales pipeline saw record growth of
£62m, or by 18% based on Mature
Annualised Revenues.
Headwinds to profitability included a slower
start-up in our China facility, a weaker
performance in Medical Spine, competitive
pressure in our VAR end market, an adverse
sales mix and a sizeable currency headwind.
Notable highlights included an award of
a technological order contract by Petrobras
for TechnipFMC, supporting our ‘Magma’
mega-programme and the sizeable volume
potential for VICTREX™ PEEK based composite
pipe (8 tonnes of VICTREX™ PEEK per
kilometre of pipe). We also secured new
business in Aerospace Composites within
the Advanced Air Mobility (‘AAM’) sector.
Delivery through our improvement actions
and by increasing differentiation compared
to our competitors remains key.
UNDERPIN THROUGH SAFETY,
QUALITY, SUSTAINABILITY AND
CAPABILITY
Safety is integral to our success and there
is nothing more important than the safety,
health and wellbeing of our employees.
Supporting our focus on SHE are our values
of Passion, Innovation and Performance. Our
safety performance since FY 2021 has seen
a 77% reduction in our recordable injury
frequency rate (‘RIFR’) to 0.16 in FY 2025
(industry average 1.5 based on US OSHA
average). During the year our Seal Sands
(UK) manufacturing facility achieved
20 years without a lost time incident,
a significant milestone.
PEOPLE & CAPABILITY
Victrex is unique in having over
1,100 employees waking up every day
focused solely on growing the opportunities
for VICTREX™ PEEK. Our culture of
innovation and of Diversity, Equity &
Inclusion remains strong, illustrated by
Victrex being listed in The Sunday Times
Best Places to Work 2025. We also secured
the Chemical Industries Association
‘Company of the Year’ award 2025.
To drive a high performance culture and
improve delivery means ensuring we have
the right behaviours. Across our global
team, our employees remain highly engaged
and eager to improve our performance,
with a strong talent agenda including
apprenticeships and early careers programmes.
Many of our employees have progressed
to much larger roles.
SUMMARY: REALISING AND
UNLOCKING OUR POTENTIAL
As I retire as CEO, I leave the business with
stronger foundations, an innovative culture
and a talented group of global employees
with Passion, Innovation and Performance at
the heart of everything we do.
Taking more extensive improvement actions
now to fully address short-term challenges and
respond to a more competitive environment
will be key. The opportunity to improve
financial performance and unlock our
significant potential over the years ahead
remains significant.
This is and will remain a fantastic company.
I look forward to seeing James Routh,
as our new CEO, building on these
strong foundations.
Jakob Sigurdsson
CEO
2 December 2025
We have also made good progress
in Quality, though there is more to do.
Our improvements to ‘Right First Time’
manufacturing support efficiency in our
manufacturing processes as well as an
enhanced customer experience.
Embedded in our business model is
Sustainability. VICTREX™ PEEK is lighter
than metal, faster to process and offers
environmental or societal benefits, for example
supporting CO2 reduction in Transport markets,
energy efficient devices, or supporting better
patient outcomes in Medical. We continue
to show how VICTREX™ PEEK has a lower
climate impact than the industry average
(details shown on pages 38 to 67 and based
on using UK monomers), which supports
our customers’ sustainability journeys.
Annual Report 2025 – Victrex plc
13
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
KEY PERFORMANCE INDICATORS
DRIVE CORE BUSINESS
Guidance for solid progress vs
FY 2025, to reflect ongoing headwinds,
e.g. Medical Spine and currency
•
Profit Improvement Plan to reduce
cost to serve (implementation in
FY 2026, full year benefits in FY 2027)
•
Increasing sales excellence &
leveraging digital solutions including
ERP system
Link to risks
3, 7, 8
(10)
Focus for FY 2026
•
121
China facility operational and
50 tonnes of product manufactured
121%
114
•
+1%
18
Underlying operating cash conversion
of 121%
49
•
100
Revenue up 1%, offset by Medical
Spine weakness
UNDERLYING OPERATING
CASH CONVERSION % F B
1
•
REVENUE
CHANGE % F
(5)
Sales volumes up 12%
11
•
15
How we performed in FY 2025
21
22
23
24
25
21
22
23
24
25
Definition
Definition
The year on year percentage change
in total revenue for the Group, in
reported currency.
Underlying operating cash conversion
is underlying operating cash flow as
a percentage of underlying operating
profit. Underlying operating cash flow
is underlying operating profit before
depreciation, amortisation and loss
on disposal, less capital expenditure,
adjusted for working capital movements.
Why it’s important
Revenue growth is the measure
chosen to reflect the structural growth
opportunities for PEEK across our
markets, with above-market growth
being the medium-term focus.
Why it’s important
Used to assess the business’ ability
to convert operating profit into cash
effectively. From FY 2025 underlying
operating cash conversion is a
metric which partly determines
bonus outcomes.
DIFFERENTIATE THROUGH INNOVATION
Increased ‘Magma’ revenue following
technological order for TechnipFMC
(by Petrobras)
21
22
23
24
25
23
9.1
•
6% of Group revenue
10.2
Clinical trial commenced for PEEK
Knee (US), building on India
regulatory submission
£9.1m
11.1
•
£18.8m
MEGA-PROGRAMME
REVENUE £M F B
18.8
Mega-programme revenue lower
at £9.1m (FY 2024: £10.2m)
17.5
•
R&D
SPEND £M F
18.6
Innovation leadership: R&D
investment at 6% of revenue
15.7
•
15.5
How we performed in FY 2025
24
25
Focus for FY 2026
•
Improve mega-programme
commercialisation & revenue
•
Progress US clinical trial for PEEK Knee
•
Continue support for TechnipFMC
and prepare for Magma scale-up
(Hybrid Flexible Pipe), driving
revenue growth
Link to risks
6, 7
Principal risks
Pages 28 to 34
14
Victrex plc – Annual Report 2025
Definition
Definition
The total Research & Development spend
that the Group has incurred.
Value of Group sales generated from
our five mega-programmes.
Why it’s important
Why it’s important
Research & Development spend at 5–6%
of sales underpins our ability to innovate
into new applications, supporting our
future growth.
Mega-programme revenue is a
measure of the adoption of our five
mega‑programmes, after a period of
investment, development and initial
market adoption/commercialisation.
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
Key to KPIs
Financial KPI
N
Non‑financial KPI
B
Linked to bonus objectives (remuneration)
L
L inked to Long Term Incentive Plan (’LTIP’)
objectives (remuneration)
CREATE & DELIVER FUTURE VALUE
L
21
22
70.9
32.0p
87.6
25
Focus for FY 2026
•
Support Magma scale-up and
increased revenues
•
Drive further milestones in PEEK Knee
•
Grow earnings per share
Link to risks
7, 8
21
22
23
23
32.0
24
19.8
Earnings per share (basic) up 62%
F
84.3
•
BASIC EARNINGS PER SHARE P
L
9%
9
Business wins in Advanced Air
Mobility (‘AAM’), supporting increased
use of VICTREX™ PEEK based
composite materials
10
•
RETURN ON
INVESTED CAPITAL % F
14
Lower return on invested capital
reflecting first full year of
China manufacturing
20
•
18
How we performed in FY 2025
24
25
Definition
Definition
Return on invested capital (‘ROIC’) is defined
as profit after tax adjusted to exclude
exceptional items net of tax, finance costs
and finance income/average adjusted
net assets. Adjusted net assets is total equity
attributable to the shareholders at the year
end excluding cash and cash equivalents,
other financial assets, retirement benefit
asset, retirement benefit obligations and
borrowings. Average adjusted net assets is
adjusted net assets at the start of the year
plus adjusted net assets at the end of the
year, divided by two.
Profit after tax divided by the
basic weighted average number
of shares. This includes the impact
of exceptional items.
Why it’s important
Earnings per share measures the
overall profitability of the Group
and demonstrates how we convert
our top-line revenue opportunities into
profitable growth for our shareholders.
Why it’s important
ROIC measures the return generated on
capital invested by the Group and provides a
metric for long-term value creation.
UNDERPIN THROUGH SAFETY, SUSTAINABILITY AND CAPABILITY
Focus for FY 2026
•
Embed Safer, Better, Together culture
•
Continue exploring options for SBTi
decarbonisation plan across all scopes
•
Drive product differentiation agenda
with customers; complete Lifecycle
Analysis plan across 80% of products
by volume and revenue
Link to risks
1, 2, 4, 5, 6
21
23
24
25
4,423
2,216
22
3,895
Achieved 40% Females in Leadership
(based on FTSE Women Leaders)
2,216
4,784
•
0.16
HOURS WORKED IN
THE COMMUNITY N
3,559
Achieved climate assessment for
80% of products by volume (Lifecycle
Analysis) with favourable impact vs
industry standard
0.16
•
OSHA RECORDABLE
INJURY RATE N B
0.18
Improved recordable injury frequency
at 0.16 (lower than OSHA industry
average of 1.5 and FY 2024 0.18)
0.2
•
0.2
How we performed in FY 2025
0.7
F
21
22
23
24
25
Definition
Definition
The US Occupational Safety and Health
Administration (‘OSHA’) is the industry
standard for recordable injuries. This is
based on total number of recordable
injuries x 200,000/total number of hours
worked (employee & contractor).
Total number of hours that Victrex
employees have volunteered in
community activities.
Why it’s important
A safe and sustainable business is the
highest priority for Victrex. Victrex
continues to be better than the industry
standard after adopting OSHA reporting
in FY 2019.
Why it’s important
Our People pillar within our ESG strategy
is key to supporting the communities
where we operate (for example in
Biodiversity activities), and supporting
our talent strategy in recruiting the
employees of tomorrow (for example
through STEM activities).
Annual Report 2025 – Victrex plc
15
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
STAKEHOLDER ENGAGEMENT
OUR STAKEHOLDER
LANDSCAPE
WHY WE ENGAGE
We place and consider the needs of all
our stakeholders – internal and external –
high on our daily agenda, listening to and
understanding the interests and concerns
of all our global stakeholder groups.
Stakeholder
EMPLOYEES
•
•
•
•
•
•
•
CUSTOMERS
• Solutions-driven culture
• Enhanced Go to Market approach (Project Vista)
• Sustainable products supporting CO2 reduction
For example, we enable environmental
& societal benefits through our products,
helping to address performance challenges
faced by our customers. This includes
through the technical or performance
benefits of our polymers and minimising
the use of resources in our own operations.
Stakeholder engagement is assessed every
year by the Board. This covers employees,
customers, investors, suppliers, regulators
and government, and our communities.
For investors, we have a proactive annual
plan of engagement, through our financial
calendar activity, investor roadshows, Annual
General Meeting, site visits or investor
conferences. Reflecting our increasingly
diverse shareholder base (with around 20%
of our shareholding in North America),
we actively engage with investors in
the UK, Europe, the US and Canada.
We continue to be collaborative with
all stakeholder groups, listening to
feedback and being open to change.
Focus areas
Safety focus
Innovative culture
Sustainability embedded in our business model
Highly motivated and talented employees
High retention rate and appropriate reward
High level of share ownership
Equal Opportunities, Diversity, Equity &
Inclusion (‘DE&I’) agenda
• Company performance
•
•
•
•
INVESTORS
& clinical benefit
Quality and regulatory support
Technical service offering
Collaboration across the supply chain
China manufacturing to support customers
• Delivery of strategy
• Alignment with shareholder interests
• Capital allocation policy and understanding
of dividend/buyback preferences
• Improvement in earnings and returns
• ESG agenda and long‑term goals
• Directors’ remuneration policy
Key to strategy
Drive core business
SUPPLIERS
Differentiate through innovation
Create and deliver future value
nderpin through safety,
U
sustainability and capability
•
•
•
•
•
•
Security of supply
ESG and Scope 3 emissions
Global supply chain
Shorter lead times
Compliance and quality
Reliability and flexibility
Strategy and KPIs
Pages 12 to 15
• Sustainability programme
COMMUNITIES
social responsibility
AND ENVIRONMENT •• People:
Planet: resource efficiency
• Products: sustainable solutions
REGULATORS AND
GOVERNMENT
16
Victrex plc – Annual Report 2025
•
•
•
•
•
Safety culture
Employee welfare & wellbeing
Product quality
Innovation
Sustainability programme
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
How the Board engages
Engagement outcomes in FY 2025
• The Board receives reports on our safety programme including the ‘Safer, Better,
• Strong safety performance since FY 2021; 77% lower RIFR rate
• 31 Professional Development Awards & 46 CEO Awards;
Together’ campaign and monitors employee training
• The Executive Directors attend Global staff briefings (quarterly), CEO Awards,
employee forums and join employee resource groups as appropriate
• The CEO takes ownership of ‘Ask the CEO’ and other intranet forums and
provides feedback at Board meetings
• Culture, talent development and succession planning are discussed at Board meetings
• The Remuneration Committee reviews workforce policies and practices
regarding reward structures and makes recommendations to the Board
• The Board considers the Employee ‘voice’ through the Workforce Engagement
Director and Employee Engagement Surveys, and reviews steps taken to
address feedback
• The Board regularly attends Victrex’s HQ and other global sites
• The Board reviews and supports the business model and the strategic alignment
with ‘Must Win’ priorities
• The Board receives reports on and monitors the Go to Market structure,
including increased regional focus and integration of digital solutions
• The Board receives reports from the Quality and Regulatory teams which
support our customers
• The Board approves key supply and development contracts
• The Board receives reports and presentations from the Sales teams and VMT
as appropriate
• The Board receives updates from the Investor Relations function at each
Board meeting
• The Executive Directors participate in global roadshows
• All Directors attend the AGM, enabling shareholder access
• The Remuneration Committee Chair consults on the remuneration policy
• The Chair and the Executive Directors have regular dialogue with investors on
performance, strategy or other matters
• The Audit Committee recommends and the Board approves the Annual Report and
financial statements, the half year results and the interim management statements
• Commercial performance and supplier relationships are discussed at Board meetings
• The Board receives reports on supply chain risk management and
engagement programmes
• The Board reviews and endorses the Supplier Code of Conduct
• Business continuity planning is reviewed by the Audit Committee and reported
on to the Board
• The CFO endorses the Company’s status as a Prompt Payment Code signatory
and reviews compliance with its principles
48 employees on Victrex apprenticeships
• Diverse and inclusive workplace, with several employee resource
groups including for Race, Ethnicity and Cultural Heritage (‘REACH’)
• Organisational Capability Review (‘OCR’) to drive succession planning
• Minimum Wage and National Living Wage, and employee
bonus scheme
• Employee Engagement Survey; strong engagement score at 76% (UK)
• Recognition of external and macro-economic factors impacting
Victrex, including below market wage growth for FY 2026
• Key milestones for commercial delivery across our ‘Must Win’ priorities
• Improved volume growth of 12%
• Record annual pipeline growth of 18%/£62m (based on Mature
Annualised Revenues)
• New digital solutions and ‘Highspot’ customer portal to showcase
Victrex’s proposition with customers
• Performance-based pricing of our products
• Board level engagement on key strategic programmes with
customers, e.g. ‘Magma’ and TechnipFMC
• Strong investor relations programme including 190 meetings hosted
•
•
•
•
•
•
•
•
•
•
•
(virtual and face to face via IR activity, roadshows or conferences)
Delivery of new investors in the UK, the US, Canada and Europe
Engagement through major investor conferences or site visits
Broad investor base: North American shareholding ~20%
Above average shareholding in ethical investment funds (ESG)
Improved understanding of strategy and delivery focus
Further progress on dual sourcing
Improved performance of third-party manufacturers
Long-term agreements on raw materials
Supplier management framework
Robust risk management of critical suppliers
Engagement on decarbonisation opportunities (supporting
our Scope 3 emission goals)
• The Corporate Responsibility Committee provides oversight of modern slavery,
human trafficking and human rights in the supply chain and recommends the
Modern slavery statement to the Board
• The Corporate Responsibility (‘CR’) Committee oversees strategic efforts
to address sustainability in the supply chain
• The CR Committee receives reports on engagement with ESG rating agencies
• The CR Committee reviews progress on Lifecycle Analysis and engagement with
customers and endorses Biodiversity partnerships
• The CR Committee receives reports on STEM Ambassadors and outreach
to schools and colleges
• The CR Committee monitors activities related to supporting our talent agenda
through local employment events and Business in the Community
• The CR Committee and Board receive reports on engagement with industry
regulators, e.g. HSE, Environment Agency, certified bodies and trade
organisations, cross-industry collaborations, and NGOs and industry bodies
• Maintained 100% electricity from renewable sources (including
new Victrex solar generation in the UK) across all global sites
• Positive accreditations across ESG benchmarks, e.g. MSCI
‘A’ rating, FTSE Russell Green Revenues Index, Apple Clean
Energy Supplier programme and Chemical Industries Association
‘Company of the Year’
• Optionality for SBTi decarbonisation roadmap
• Global volunteering including 2,216 employee hours committed
• Further improved strong SHE performance including OSHA
recordable injury rate at 0.16 (industry average 1.5)
• Collaboration with academia including for sustainable chemistry
opportunities (process of manufacturing PEEK)
• 3D printing collaborations
• 50% increase in governmental engagement in FY 2025,
particularly on energy costs and decarbonisation agenda
Annual Report 2025 – Victrex plc
17
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
STAKEHOLDER ENGAGEMENT CONTINUED
HOW WE ENGAGE
WITH OUR STAKEHOLDERS
During the year ended 30 September 2025, the Board of Victrex plc believes, as individuals and collectively, it has considered stakeholder
interests in its decision making, while ensuring the long-term success of the Company is promoted in pursuit of our strategic aims.
Our section 172 statement is set out on the following pages, and should be read in conjunction with our stakeholder engagement
statement on pages 16 and 17. It describes how the Directors have had regard to stakeholders’ interests when discharging their duties
under section 172 and includes examples of key decisions taken during the year. Where appropriate, Board papers include a stakeholder
assessment to support the Board in its duties. The Victrex governance framework from page 75 describes the Board level governance
and how the Board delegates its authority. A summary of stakeholder groups considered as part of the Board’s activities is provided on
pages 78 and 79 of the Corporate governance report.
Alongside the key decisions summarised in this statement, the below table outlines other areas of this report which detail how the Directors
have had regard to the section 172 factors. Engagement with investors is described on pages 16, 17 and 98.
A
B
The likely consequences of any decision in the long term
The Board has an established programme of business and
sets strategy with a view to long-term success and to deliver
our purpose.
•
The interests of the company’s employees
Our people are essential to delivering performance and growth.
We invest time and resources in employee engagement,
training and development. Our Workforce Engagement NED
gathers the views of the workforce on behalf of the Board.
When making key decisions, the Board considers employee
views gathered through engagement mechanisms.
•
Our purpose, page 3
Our business model, pages 8 and 9
• Our strategy and strategic progress, pages 1–67
• Board outcomes, pages 16–19
•
•
•
•
•
•
•
•
C
D
E
The need to foster the company’s business relationships
with suppliers, customers and others
Our relationships with customers, suppliers, governments,
regulators and partners are core to our strategy and business
model and building a sustainable business. The Board receives
updates on engagement across the Group at meetings,
including customer ‘on time in full’ metrics and the fair
treatment and payment of suppliers and reviews the Modern
slavery and human trafficking statement annually.
•
The impact of the company’s operations on the
community and the environment
Our sites are positive contributors to their local communities
as employers and also through apprenticeships, STEM
activities in schools and colleges, and community activities.
•
The desirability of the company maintaining
a reputation for high standards of business
Our sustainability initiatives are consistent with building our
standing as a good corporate citizen. The Board demands high
standards of conduct and expects management to be mindful
of how and with whom business is conducted. The Group will
decline to do business with third parties that display poor
business conduct or do not pass applicable onboarding checks.
•
•
•
•
•
•
Business model, pages 8 and 9
Stakeholder engagement, pages 16 and 17
• Strategic progress, pages 1–67
• Sustainability report, pages 38–67
• TCFD, pages 42–49
•
•
•
•
•
•
18
The need to act fairly between members of
the company
It’s not always possible to provide positive outcomes for all
stakeholders and the Board sometimes has to make decisions
based on balancing the competing priorities of stakeholders.
Victrex plc – Annual Report 2025
Markets, pages 26 and 27
Business model, pages 8 and 9
Stakeholder engagement, pages 16 and 17
Strategic progress, pages 1–67
Modern slavery, page 65
Payment practices reporting, page 118
•
•
F
Business model, pages 8 and 9
Stakeholder engagement, pages 16 and 17
People and culture, pages 52–54 and 77
Health and safety, page 63
Employee engagement, pages 16 and 17 and 52–54
Workforce NED report, page 81
Directors’ remuneration report, pages 95–116
Whistleblowing, page 65
Business model, pages 8 and 9
Health and safety, page 63
TCFD, pages 42–49
Non-financial and sustainability information statement,
pages 66 and 67
Risk management, pages 28–34
Audit Committee report, pages 86–92
Whistleblowing, page 65
Modern slavery, pages 65
Business model, pages 8 and 9
Stakeholder engagement, pages 16 and 17
• Strategic progress, pages 1–67
• Board outcomes, pages 16–19
• Directors’ remuneration report, pages 95–116
•
•
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
DELIVERING FOR OUR STAKEHOLDERS
CEO SUCCESSION – FOCUS ON
STRATEGY EXECUTION
NEW CHINA FACILITY – IMPROVING
OPERATIONAL PERFORMANCE
With the retirement of Jakob Sigurdsson as CEO after eight
years in the role, the Board considered all of our stakeholders,
particularly during the planning and transition phase.
With the start-up of our new manufacturing facility in Panjin,
(China) in the second half of 2024, we were able to further
differentiate our business. Our Victrex Panjin facility will
further support regional growth opportunities in China
(‘China for China’) with a type 2 manufacturing process
for Victrex ‘Elementary’ PEEK.
A defining point for the recruitment of a new CEO was how
Victrex can focus harder on strategy execution and delivery,
whether it be addressing increased competition, how we
serve our customers or how we can further differentiate
by progressing our mega-programmes or ensuring that we
improve our operational effectiveness and reduce our cost
to serve customers.
As a consequence, delivery and execution of strategy were
key requirements, as well as balancing the consideration of
experience as a listed company CEO, a track record of delivery
for a global customer base, and being able to drive an
innovative culture for employees.
This is a strategic asset for Victrex in enabling further growth
opportunities in the region, whilst addressing competitive
challenges there. Initial operational issues during start-up
meant engagement with stakeholders has been required to
improve operational performance and commercial delivery.
This was largely achieved by the end of FY 2025, with steady
ramp-up anticipated in FY 2026.
The Board visited China in October 2024. The Board consideration
for stakeholders aligned to section 172 included:
Board consideration for stakeholders aligned to section 172 included:
Stakeholder
Section 172 factor considerations
Stakeholder
Section 172 factor considerations
Employees
Customers
The Board’s focus on a CEO with experience
in our end markets and the ability to enhance
our Go to Market approach and customer
experience to ensure we retain our position
as a global leader.
How we could utilise our China and UK-based
engineering teams to resolve initial
operational challenges, with good progress
being made by the financial year end. Safety
performance in a new geography and a new
asset also remains our highest priority.
Investors
Experience in delivering an improved
financial performance for investors on a
global basis, supporting how we can break out
of what has been and remains a challenging
period for global chemical companies.
Customers
Employees
Driving a high performance culture as well
as reducing our cost to serve and ensuring our
cost base is appropriate in an increasingly
competitive environment.
The clear need to deliver for our customers
based on initial orders during FY 2025 and
ensure a smooth customer experience. Several
Western-based customers established facilities
in China to drive growth underpinned by
Victrex materials, with customer deliveries
being fulfilled through the financial year.
Suppliers
Initial operational issues meant the
requirement to keep our suppliers informed
during start-up and operational ramp-up.
This helped support a smooth transition
in the first full year of operation.
The outcome and impact on the long-term sustainable
success of Victrex: James joins Victrex with effect from
1 January 2026. This appointment reflects the Board’s
commitment to aligning leadership capability with stakeholder
priorities and ensuring Victrex is well positioned to enhance
strategy execution, deliver sustainable growth and improve
operational excellence in an increasingly competitive landscape.
Link to section 172
A
B
C
F
The outcome and impact on the long-term sustainable
success of Victrex: the collaborative efforts of the UK and
China-based teams led to improved performance by the year
end, ensuring we can supply customers in full. This supports
customer trust and satisfaction as we further build out our
China growth opportunities.
Link to section 172
A
B
C
D
E
Annual Report 2025 – Victrex plc
19
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
FINANCIAL REVIEW
STRONG VOLUMES,
WEAKER PBT
Volume (t)
Transport (Aero & Auto)
Growth
1,012
1,022
-1%
Growth
454
+2%
705
604
+17%
VARs
1,797
1,488
+21%
Sustainable Solutions
3,978
3,568
+11%
233.9
229.1
+2%
186
163
+14%
58.8
61.9
-5%
4,164
3,731
+12%
292.7
291.0
+1%
OPERATING REVIEW
STRONG VOLUMES, DRIVEN BY
SUSTAINABLE SOLUTIONS
Group sales volume of 4,164 tonnes was up
12% on the prior year (FY 2024: 3,731 tonnes),
driven by Sustainable Solutions and in
particular the end markets of Value Added
Resellers (‘VARs’) and Energy & Industrial.
REVENUE UP 1%, REFLECTING
SALES MIX, WEAKER MEDICAL
SPINE AND CURRENCY
FY 2025 Group revenue was up 1% at
£292.7m (FY 2024: £291.0m) and up 3%
in constant currency. Performance reflects
that whilst sales volume was strong, revenue
growth lagged volume growth due to
improved performance being concentrated
in VARs and Energy & Industrial end markets,
as well as revenues being much softer in
Medical Spine.
Sales volume momentum continued in Q4,
with sales volume up 7% (Q4 volumes of
1,089 tonnes vs Q4 2024: 1,015 tonnes),
and Group revenue slightly down at £75.5m
(Q4 2024: £77.7m), reflecting a continuation
of sales mix and Medical Spine weakness.
Victrex plc – Annual Report 2025
FY 2024
464
SOLID Q4 PERFORMANCE
MOMENTUM
20
FY 2025
Energy & Industrial
Total Group
Ian Melling
CFO
FY 2024
Electronics
Medical
FY 2025 WAS A
CHALLENGING YEAR
FOR VICTREX.
WHILST WE DELIVERED
STRONG SALES VOLUMES,
STRONG CASH CONVERSION
AND RESULTS WERE IN-LINE
WITH OUR MOST RECENT
GUIDANCE, SALES MIX,
CURRENCY AND CHINA
START-UP COSTS LED TO
A WEAKER PROFIT BEFORE
TAX (PBT) PERFORMANCE.
Revenue (£m)
FY 2025
ASP OF £70/KG, DRIVEN BY SALES
MIX AND CURRENCY; ROBUST
LFL PRICING
Our average selling price (‘ASP’) of £70.3/kg
was in line with our most recent guidance
and down 10% on the prior year (down 7%
in constant currency) primarily due to the
impact of sales mix, weaker Medical Spine
and currency moving adversely during the
year. Approximately 80% of the year on
year movement was due to sales mix and
currency. Like for like (‘LFL’) pricing was
robust across key end markets outside of
VARs and Energy & Industrial, with more
competitive pressure in VARs.
In cases where price has reduced, this has
reflected the opportunity to regain business
(for example in Energy & Industrial) or has
been in response to competitive activity,
including from less established Asian
manufacturers. The advantages and
differentiation of using Victrex products
alongside our technical service and
application development capabilities
(‘delivering solutions, not just products’)
remain strong.
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
SELF-HELP: GO TO MARKET
AND INITIAL BENEFITS FROM
PROJECT VISTA
‘MAGMA’ KEY MILESTONE
SUPPORTS COMMERCIAL
ROADMAP
FY 2025 saw some initial benefits of our
‘self-help’ and improvement actions under
Project Vista. These included how we Go to
Market and serve our customers, and through
digital tools. This supported volume growth
and a record sales pipeline build in FY 2025
of £62m, or an 18% increase, with Mature
Annualised Revenues (‘MAR’) at £414m
(FY 2024: £352m). Mature Annualised
Revenues rely on all sales targets being
converted, with typical conversion rates
being lower than the full value of the sales
pipeline. We also benefited from £2m
of annualised procurement savings.
In our ‘Magma’ programme, which supports
a composite pipe solution for existing and
future oil and gas fields based on VICTREX TM
PEEK, the technological contract order –
from Petrobras to TechnipFMC – was
announced in May 2025. The final elements
of qualification work are being completed
during FY 2026, providing improved visibility
on the ramp-up requirements from our
customer, TechnipFMC, and likely timing
for revenues to step-up.
SUSTAINABLE PRODUCT REVENUES
Victrex has strong alignment to megatrends
like CO2 reduction, energy efficiency
and clinical innovation, supporting the
commercial use of VICTREX™ PEEK and
enabling environmental and societal benefit
for our customers. End market alignment
to these megatrends includes Aerospace,
Automotive and Medical, with some
applications in Electronics and Energy
& Industrial included in our measure of
sustainable product revenues2. In FY 2025,
53% of our revenues were based on
sustainable products (FY 2024 (restated): 56%),
with weaker Medical and stronger VARs
offsetting the year on year comparative.
MEGA-PROGRAMME REVENUES
IMPACTED BY E-MOBILITY AND
TRAUMA ADOPTION
Despite a key milestone and increased
revenue for our Magma programme, and
technical milestones in Aerospace Composites
and Knee, FY 2025 mega-programme
revenues totalled £9.1m, lower than the prior
year (FY 2024: £10.2m). Lower revenues in
E-mobility for 800-volt platforms and a slower
ramp-up in Trauma, due to regulatory timing,
impacted progress.
As part of our Profit Improvement Plan,
we are assessing the shape of our product
portfolio, which may consider prioritising
where we invest in our mega-programmes
(mega-programmes are defined as offering
peak year revenues above £50m).
FY 2025 key milestones in our
mega-programme portfolio included:
•
Aerospace Composites:
•
•
E-mobility:
•
•
Anticipated volumes starting to scale
up from FY 2026 onwards, subject to
the final commercial roadmap
between TechnipFMC and Petrobras.
Trauma Plates:
•
•
Lower revenues but additional
platforms to support 800 volt electric
vehicles (‘EVs’).
Magma:
•
•
Business wins in Advanced Air
Mobility (‘AAM’) to support short
to medium-term growth, as AAM
applications focus on lightweight
and durable materials.
Regulatory submission for six new
plates in China, launching in FY 2026.
PEEK Knee:
•
First patient implants in US clinical trial,
with 85 patients implanted globally,
including 20 in the US.
•
Regulatory process ongoing in India,
with regulatory submission pathways
being prepared for other geographies.
PEEK-BASED
‘MAGMA’ M-PIPE®
Hybrid Flexible Pipe (‘HFP’) is a
Thermoplastic Composite Pipe based
on VICTREX™ PEEK
In May 2025, TechnipFMC announced
that it had secured a technological order
contract from Petrobras SA (Brazil). This order
supports the pathway towards qualification
and a potentially significant multi-year
opportunity for Victrex’s ‘Magma’ megaprogramme, which is based on VICTREX TM
PEEK polymer, Victrex composite tape and
Victrex pipe extrusion know-how. The
Hybrid Flexible Pipe offers a sustainable
and durable alternative for the industry.
Approximately 50% lighter than steel in
water, HFP seeks to address the stress
corrosion cracking issues of metal based
pipes in deepwater fields within Brazil.
50%
lighter than steel in water
Visit victrex.com/en/
magma-m-pipe
Annual Report 2025 – Victrex plc
21
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
FINANCIAL REVIEW CONTINUED
OPERATING REVIEW
CONTINUED
The impact of increased price competition
was felt primarily within VARs and Energy
& Industrial, despite strong volumes.
INNOVATION INVESTMENT
Gross margin was slightly higher at 37.8%
(FY 2024 (restated): 37.1%) with the benefit
of improved volumes through our UK plants
and lower raw material costs partially offset
by annualised costs for our new China
facility, sales mix and currency.
Research & Development investment totalled
6% of revenues this year, at £18.8m (FY 2024:
6% or £17.5m). The focus of incremental
growth and innovation investment in
the near term remains in our Medical
Acceleration programme. We also saw
increasing use of digital tools and digital
modelling to support customers this year,
including R&D.
GOING FURTHER IN FY 2026:
PROFIT IMPROVEMENT PLAN
Our Profit Improvement Plan will lead to
a more agile and delivery focused growth
business. Full year benefits will be realised
in FY 2027, with initial benefits in H2 2026.
We are targeting annualised cost savings
of at least £10m, with a cost to deliver
(exceptional items) of approximately £10m
incurred in FY 2026. Our initial focus will be
on cost of manufacture and cost efficiency
actions, as well as simplifying our portfolio.
We will implement these actions during FY
2026, led by our incoming Chief Executive,
James Routh.
DIVISIONAL PERFORMANCE
Full year revenue in Sustainable Solutions
was up 2% at £233.9m (FY 2024 (restated in
note 2): £229.1m), driven by VARs (volumes
up 21%) and Energy & Industrial (volumes
up 17%), resulting in a softer sales mix.
Revenue in constant currency was up 5%.
The initial benefits of Project Vista and
our Go to Market approach supported
performance in FY 2025, including regaining
business and using digital solutions to
support customers and increase our key
account management capabilities.
Geographically, North America showed
volume growth vs the prior year, driven by
a better performance in Energy & Industrial
and VARs. Europe also saw improvement
through VARs, with Asia-Pacific also ahead,
supported by Electronics. Asia-Pacific, and
China specifically, remains our fastest growing
region over recent years. North America was
up 26% at 769 tonnes (FY 2024: 612 tonnes);
Europe was up 8% at 2,224 tonnes (FY 2024:
2,062 tonnes) and Asia-Pacific was up 11%
at 1,171 tonnes (FY 2024: 1,057 tonnes).
In Medical, we saw a mixed picture, with
Non-Spine revenues up 7% and Spine
revenues down 28%. Within Non-Spine,
Non Implantable revenues (which comprise
less than one-third of Non-Spine, or less
than 20% of total Medical revenues) were
up 12%. Overall Medical revenue was down
5% at £58.8m (FY 2024 (restated): £61.9m).
Our Non-Spine business grew strongly
across a range of applications with particular
highlights in cranio-maxillofacial (‘CMF’)
surgery, cardio devices and other medical
applications in a broad range of geographies.
Destocking appears to be over in
these segments.
market share shifts amongst medical device
companies, including the withdrawal of
some of our Western customers from that
market. These impacts will not necessarily
recur annually, although these share shifts
have resulted in a lower price point going
forward.
We continue to see a healthy growth rate
in clinical procedures, which underpins our
mid-term opportunities. Medical is now a
much more diverse business than historically,
with increasing penetration in Cardio,
Orthopaedics and Drug Delivery. Revenues
in Medical were 26% Spine and 74%
Non-Spine (FY 2024 (restated): 34% Spine
and 66% Non-Spine).
Average selling price in Medical reflects a wide
divergence of applications, from Non-Spine
(which also includes Non-Implantable, at the
lower end of the pricing spectrum) and Spine.
Spine and various Non-Spine applications,
including Cardio applications, are significantly
higher than divisional ASP.
Gross profit was £44.1m (FY 2024 (restated):
£49.4m) and gross margin was lower at 75.0%
(FY 2024 (restated): 79.8%), which reflects
the impact of sales mix (more Non-Spine vs
Spine) and currency. Geographically, revenues
in the US and Europe were 8% and 6%
lower respectively, with Asia revenues
up 1%.
In Spine we continued to be impacted
by the trends away from PEEK towards
expandable and porous titanium cages,
primarily in the US market. In China there
was an impact from volume-based pricing
(‘VBP’) which caused price reductions and
OUR UPDATED CAPITAL ALLOCATION POLICY:
MAINTAIN BALANCE SHEET STRENGTH
Share buybacks
• Incremental returns if no
investment requirements
Capex
Investment
Regular dividends
• Capex at low end of
c.8–10% of sales
• Growth investment
or capability: e.g.
Medical Acceleration
• Dividends maintained at
current levels provided
net debt/EBITDA
does not exceed the
0.5x-1.0x range
• No capacity spend in
current 5 year plan
TARGET TO MAINTAIN NET DEBT/EBITDA IN 0.5x - 1.0x RANGE
•
22
EXCESS CASH RETURNS CONSIDERED (VIA SHARE BUYBACKS OR
SPECIAL DIVIDENDS) WHEN NET DEBT/EBITDA MOVES
SUSTAINABLY <0.5x
Victrex plc – Annual Report 2025
• Optionality for modest
buybacks when ND/
EBITDA moves <0.5x
EXCESS CASH
RETURN OPTIONS
Special dividends
• Incremental returns if no
investment requirements
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL REVIEW
GROSS PROFIT SLIGHTLY LOWER
ON CHINA PLANT START-UP COSTS
AND CURRENCY HEADWIND
Gross profit was down 1% at £132.6m
(FY 2024: £134.3m), driven by currency, the
softer ASP and the annualised costs from
our new China manufacturing facility
(including annualised depreciation costs),
alongside wage inflation. Gross profit was up
5% in constant currency. With production
volumes of PEEK approximately 30% higher
in FY 2025 following a period of destocking
in FY 2024, we saw a positive impact from
higher asset utilisation, alongside the benefit
of lower raw material prices. This represented
a total tailwind in FY 2025 of approximately
£10.7m. In FY 2026, with some further
inventory unwind, production is likely to be
broadly similar to FY 2025. We also have an
opportunity to realise further raw material
savings, building on an improved focus on
procurement, with a £2m saving in this
area during FY 2025.
GROSS MARGIN OF 45.3%,
REFLECTING SALES MIX,
CURRENCY AND CHINA
PLANT COSTS
Full year Group gross margin of 45.3%
was in line with our most recent guidance,
90 basis points (‘bps’) lower than last year
(FY 2024: 46.2%), driven by a softer ASP
within Sustainable Solutions (more VARs and
Energy & Industrial) and the annualised costs
(£4m adverse year on year impact vs FY 2024
and £8m full year operating loss for FY 2025)
from our China manufacturing facility,
alongside currency. Excluding the impact of
the China plant start-up, gross margin was
47.7% (FY 2024: 47.0%).
For FY 2026, with sales mix expected to
be similar and production levels relatively
unchanged compared to FY 2025, based
on current assumptions, we anticipate gross
margin will be similar. Any upside will be
driven by Continuous Improvement (‘CI’)
programmes and raw material savings. Whilst
our China facility is expected to see increased
volumes, it will remain loss making and cash
negative in the current year. Improvement
in our China facility during FY 2026 would
support a limited benefit to gross margin
improvement, as the facility continues to
build towards break-even volumes.
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
Victrex has seen the fastest growth coming
from China over recent years, with the new
Panjin plant helping to further bolster our
existing presence in the region and support
additional medium term growth.
PROGRESS IN NEW CHINA
MANUFACTURING FACILITIES
We were able to deliver in line with
customer demand by the end of the year,
with approximately 50 tonnes being
produced. Our taskforce, involving
manufacturing, engineering and
commercial teams, helped us to deliver
initial improvement in manufacturing,
with active management of the facility
supporting an expected gradual increase
in volumes during FY 2026. This production
facility helps to broaden our portfolio of
PEEK grades, with a new ‘Elementary’
type 2 PEEK polymer grade tailored to
the local market.
Separately from our new manufacturing
facility, in our existing and long standing
commercial business within China, overall
demand, within our target end markets,
remains positive and it continues to be our
fastest growing region.
GAINS & LOSSES ON FOREIGN
CURRENCY NET HEDGING
Fair value gains and losses on foreign
currency contracts in FY 2025 were a gain
of £3.7m (FY 2024: gain of £5.2m), arising
from contracts where the deal rate obtained
in advance was favourable to the average
exchange rate prevailing at the date of the
related hedged transactions. We continue
to hedge the net currency exposure, which
reflects the diversity of our customer and
cost base across regions.
Our hedging policy is kept under review, for
the duration of hedging, level of cover and
currencies covered. It requires that at least
80% of our US Dollar and Euro forecast cash
flow exposure is hedged for the first six
months, then at least 75% for the second
six months of any rolling twelve-month
period. As at the date of this report,
our level of cover for FY 2026 was
approximately 80%.
FURTHER ADVERSE IMPACT FROM
CURRENCY IN FY 2026
UNDERLYING OPERATING
OVERHEADS1 SLIGHTLY AHEAD
EXCLUDING WAGE INFLATION &
PARTIAL EMPLOYEE REWARD
Total underlying operating overheads1,
which exclude exceptional items of £8.6m,
increased by 14% to £84.2m (FY 2024:
£74.0m). The majority of this increase
related to employee related expenditure,
primarily £3.7m of non-cash share incentives
to support retention. The remainder included
wage inflation, the UK government imposed
employer national insurance (‘NI’) increase,
and partial bonus awards to employees
following three years of low to no payout
under existing employee reward schemes.
Partial bonus payments reflected metrics
achieved on operating cash conversion and
some strategic objectives, with no awards
made under the main profit-based metric
(profit is 60% weighting for the all
employee annual bonus).
The increase in share-based charges reflects
firstly, the absence of charges in the prior
year, due to the reversal of accruals from
prior years for share plans failing to vest (for
all employees, including Executive Directors).
Secondly, the share incentive structure for
employees has changed, as previously
communicated, thereby supporting
retention. Share incentive schemes for
Executive Directors are unchanged.
For Executive Directors and Victrex
Management Team (‘VMT’) members,
the Remuneration Committee used its
discretion to conclude that partial bonuses
for FY 2025 should be further reduced,
noting the shareholder experience during
the year.
Underlying operating overheads, when
excluding the effects of wage inflation,
the employer NI increase, Executive
recruitment fees and partial employee
reward, were up 2%. Tight cost control
prevails, including on recruitment, travel and
reductions in discretionary spend.
Innovation spend was primarily supporting
our Medical Acceleration programme.
In line with our Profit Improvement Plan,
additional actions to improve efficiencies
and reduce our cost base and cost to serve
will be the focus for the year ahead.
Based on spot rates and currency contracts
in place at the date of this report, currency
represents a £2m–£3m headwind to underlying
PBT in FY 2026, which will be weighted to
the first half. This reflects the strengthening
of Sterling, particularly against the US Dollar
and some Asian currencies.
Annual Report 2025 – Victrex plc
23
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
FINANCIAL REVIEW CONTINUED
FINANCIAL REVIEW
CONTINUED
NET INTEREST EXPENSE
Net interest expense increased to £2.0m
in FY 2025 (FY 2024: net interest expense of
£1.2m) and we expect a similar level through
FY 2026. The increase is driven by the
annualised impact of our China loan used to
fund the investment in manufacturing assets
which started to be expensed (rather than
capitalised) from H2 2024.
UNDERLYING PBT
Underlying PBT of £46.4m was down 21%
(FY 2024: £59.1m). In constant currency,
underlying PBT was down 10%.
Despite strong volumes, a significantly
adverse sales mix (across both divisions) and
some price pressure in VARs resulted in a
weaker drop through to PBT. Whilst the
Group saw improved asset utilisation across
our asset base, costs from our new China
facility recorded an £8m loss. The currency
headwind was £8.0m.
LOWER EXCEPTIONAL ITEMS
FY 2025 saw the final costs of implementing
our ERP system, and associated business
improvements, including the Project Vista
programme. Our ERP system – Microsoft D365
– is helping to drive a stronger customer
facing platform, including digital tools for
sales and our Research & Development
(‘R&D’) teams. We have also recognised a
£4.0m loss from our equity investment in
Surface Generation, which included the
non-cash reduction in the fair value of our
investment to £nil and the write off of
associated receivables.
Taking into account one-off costs associated
with our new Profit Improvement Plan,
we anticipate exceptional items will be
approximately £10m for FY 2026.
REPORTED PBT UP 44%
Reported PBT increased by 44% to £33.8m
(FY 2024: £23.4m) as we saw a much lower
value of exceptional items compared to the
prior year. FY 2025 reflected exceptional
items of £12.6m in total (FY 2024: £35.7m),
mainly comprising ERP system costs, with our
Microsoft D365 system being successfully
implemented, and associated costs from
Project Vista.
EARNINGS PER SHARE UP 62%
Basic earnings per share (‘EPS’) of 32.0p was
up 62% on the prior year (FY 2024: 19.8p),
reflecting the improvement in reported PBT,
including the effect of exceptional items
being lower. Underlying EPS was down 15%
at 43.9p (FY 2024: 51.7p).
24
Victrex plc – Annual Report 2025
TAXATION
LOWER CAPITAL EXPENDITURE
In FY 2025 the effective tax rate was 26.3%
(FY 2024: 32.5%) and tax paid was £4.4m
(FY 2024: £4.3m). The year on year reduction
was driven by a higher proportion of current
year exceptional items being tax deductible.
The underlying effective rate was 23.9%
(FY 2024: 22.2%) with the increase
attributed to the higher losses in China
where no deferred tax asset is recognised.
Our asset portfolio is well invested and
underpins our core business and future growth
programmes. Cash capital expenditure reduced
to £21.8m (FY 2024: £32.6m), below the
lower end of our 8–10% of Group revenues
guidance. Our largest investment in the year
was in an essential safety and regulatory project
at our monomer plant in Rotherham, UK.
Our mid-term guidance for the effective
tax rate is marginally higher than previously
communicated at 15%–19% (previously
14%–18%), due to an increase in the forecast
proportion of profits arising outside the UK,
therefore not benefiting from the UK Patent
Box regime. In FY 2026 the effective rate
is likely to again exceed the top end of the
range, with no asset recognised for carried
forward losses in China and the proportion
of UK profits available for Patent Box being
the key drivers.
BALANCE SHEET
Retaining a strong balance sheet to support
our global customers – and reflecting the
nature of our long-term programmes – remains
key. Net assets at 30 September 2025
totalled £431.2m (FY 2024: £461.6m).
ROIC1
Return on invested capital (‘ROIC’) is one
of our strategic KPIs. Our ROIC in FY 2025
was 9% (FY 2024: 10%). This declined due
to the reduction in underlying profits which
was partially mitigated by a reduction in
average invested capital driven by asset
impairments in both the current and
prior year.
INVENTORY UNWIND
Following our UK Asset Improvement
programme in FY 2023, we commenced
inventory unwind during FY 2024. In FY 2025,
we saw further progress, resulting in closing
inventory reaching £109.7m (FY 2024:
£115.1m). Our goal of approximately £100m
is higher than historical levels, but reflects
the broader business, asset and geographic
portfolio. This includes an increased range
of polymer grades and product forms
to support a wider customer base. For
FY 2026, we expect to see some additional
progress on inventory unwind, with broadly
similar production levels from UK assets.
Mid-term capital expenditure guidance is
unchanged (8–10% of revenues) but is likely
to remain below these levels in the short
term, with production capacity already in
place to support our five-year strategic plan.
Following a review of options to phase
investment in support of decarbonisation,
any major step-up in related capital
expenditure would be phased in FY 2028
and beyond, whilst noting our interim
science-based targets (‘SBTi’) in 2032. This
will only commence subject to available
technology and visibility towards a
decarbonised grid in the UK, as well
as affordability.
STRONG OPERATING CASH
CONVERSION1 OF 121%
Cash generated from operations was
down 14% at £75.9m (FY 2024: £88.7m)
reflecting the lower operating profit and the
significant benefit of inventory unwind in
the prior year. Underlying operating cash
conversion1 improved to 121% (FY 2024:
114%) driven by lower capital expenditure.
In June 2025 we paid the 2025 interim
dividend of 13.42p/share at a value of
£11.7m. Net debt at 30 September 2025
was £24.8m (FY 2024: £21.1m), including
cash of £24.2m (FY 2024: £29.3m).
The Group has continued to utilise the UK
revolving credit facility (‘RCF’) to support
payment of the final dividend in FY 2025
and FY 2024 before being fully repaid by
30 September in each year. Borrowings,
including lease liabilities, at 30 September 2025
were £49.0m (FY 2024: £50.4m).
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
UPDATED CAPITAL ALLOCATION
POLICY
RECOGNITION IN A CHALLENGING
ENVIRONMENT
Alongside our Profit Improvement Plan and
incremental actions to drive performance
improvement, we are maintaining the
strength of our balance sheet, which is a key
consideration for customers and investors.
Reflecting all stakeholder interests, we will
target maintaining net debt/EBITDA1 in a
range of 0.5x–1.0x.
In a challenging environment, our culture of
innovation remains strong. With the Chemical
industry seeing continuing challenges during
FY 2025, we were pleased to be recognised
as Company of the Year by the Chemical
Industries Association.
Dividends will be maintained vs FY 2024,
with the Group securing additional term debt
to reduce reliance on the RCF. The FY 2025
proposed final dividend is 46.14p (FY 2024:
46.14p). We will maintain dividends at these
levels provided the net debt/EBITDA1 target
range of 0.5x-1.0x is not exceeded. This
ensures that the balance sheet strength, for
which Victrex is well known, is maintained.
Additional returns of cash, via share
buybacks, or special dividends, will be
considered when net debt levels fall
sustainably below the low end of this range.
1 Alternative performance measures are defined
in note 26.
2 Sustainable revenues as a % of total revenues
is another internal metric calculated as the %
of revenue earned from sustainable products,
which are defined as those which offer a
quantifiable environmental or societal benefit.
These are primarily in Automotive and
Aerospace (supporting CO2 reduction) but also
in Energy and Industrial and Electronics (e.g.
wind energy applications, or those which
support energy efficiency) and Medical (both
implantable and non-implantable), supporting
better patient outcomes.
Ian Melling
CFO
2 December 2025
Annual Report 2025 – Victrex plc
25
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
DIVISIONAL & END MARKET SUMMARY
SUSTAINABLE SOLUTIONS
STRONG VOLUMES, SOFTER SALES MIX
SUSTAINABLE SOLUTIONS
REVENUE
SUSTAINABLE SOLUTIONS
GROSS PROFIT
+2% vs FY 2024*
+4% vs FY 2024*
£233.9m
£88.5m
12 months
ended
30 Sept
2025
£m
12 months
ended
30 Sept
2024 *
£m
%
change
(reported)
%
change
(constant
currency)
Revenue
233.9
229.1
2%
5%
Gross profit
88.5
84.9
4%
13%
- Restated to reflect non-implantable medical reclassification from Sustainable Solutions
to Medical segment (see note 2).
ELECTRONICS
Within Electronics, Global Semiconductor
and Consumer Electronics markets comprise
approximately two-thirds of our exposure.
Electronics sales volumes grew 2% at 464
tonnes (FY 2024: 454 tonnes), though we
saw some slowdown in the second half year,
in line with market data.
VICTREX™ PEEK has a range of applications
serving Electronics, which include CMP rings
(for Semiconductor), material used in the
chip manufacturing process and to support
smart devices. In smart devices, our APTIV™
film underpins small space acoustic
applications, including in speaker diaphragms
and related components. We also continue
to see business in home appliances and
related applications. Opportunities driven
by 6G mobile applications and related
areas offer good growth prospects.
ENERGY & INDUSTRIAL (‘E&I’)
VICTREX™ PEEK has a long-standing track
record of durability and performance in
many demanding Oil & Gas applications,
where lightweighting, durability and
performance are key. Metal replacement
remains a key trend and with higher activity
levels within the industry, sales volume of
705 tonnes was up 17% on the prior year
(FY 2024: 604 tonnes).
General Industrial accounts for over half of
the sales volume within this end-market.
Our development of VICTREX™ PEEK as a
PFAS (Per and Polyfluoroalkyl chemicals)
alternative continues to make good progress.
26
Victrex plc – Annual Report 2025
TRANSPORT (AUTOMOTIVE
& AEROSPACE)
Our products have supported ‘avoided
emissions’ for over 30 years, through
underpinning CO2 emission reduction, which
is a key megatrend. We replace metal on
light vehicles and on a range of aircraft, with
content per plane currently varying from 100kg
to 500kg, dependent on the application.
Transport sales volume was down 1% to
1,012 tonnes (FY 2024: 1,022 tonnes), with
Aerospace down 2% and Automotive down
1%. This performance reflects order phasing
and supply chain challenges with specific
customers in Aerospace vs strong growth
in FY 2024, alongside new business in
China having a slower ramp up. We remain
optimistic for Aerospace in FY 2026, with
new business wins and an expected
ramp-up in China, with Victrex having
material specified on platforms where build
rates are increasing, including COMAC’s
C919 aircraft, which forecasts build rates
increasing over the coming years. During
FY 2025, we also secured a key business
win in Advanced Air Mobility (‘AAM’),
where lighter materials and strength are
key requirements. In Automotive, industry
forecasts (S&P Global) suggest car production
in 2025 of approximately 1% growth versus
2024, or 89.3 million cars built. We saw
a slightly improved performance in
Automotive during H2 2025.
VALUE ADDED RESELLERS (‘VARS’)
Our VARs end market sees VICTREX™ PEEK
processed into stock shapes or compounds,
for onward sale into multiple supply chains.
VARs, who are amongst our largest
customers, are integral to our route to
market and innovation partnerships with
major customers, helping us to grow the
market for VICTREX™ PEEK. It is our lowest
cost to serve area, with limited R&D and a
low-touch business model to support
long-term customers. VARs sales
volume was up 21% to 1,797 tonnes
(FY 2024: 1,488 tonnes).
STRATEGIC REPORT
CORPORATE GOVERNANCE
FINANCIAL STATEMENTS
SHAREHOLDER INFORMATION
MEDICAL
GOOD GROWTH IN NON-SPINE AND
NON-IMPLANTABLE; SPINE REMAINS
CHALLENGING
MEDICAL REVENUE
MEDICAL GROSS PROFIT
-5% vs FY 2024*
-11% vs FY 2024*
£58.8m
£44.1m
12 months
ended
30 Sept
2025
£m
12 months
ended
30 Sept
2024 *
£m
%
change
(reported)
%
change
(constant
currency)
Revenue
58.8
61.9
-5%
-2%
Gross profit
44.1
49.4
-11%
-7%
- Restated to reflect non-implantable medical reclassification from Sustainable Solutions to
Medical segment (see note 2).
CHALLENGES IN SPINE
Whilst we remain cautious about the
prospects in Spine, PEEK retains advantages